The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
Adverse Drug Event Reporting: The Roles of Consumers and Health-Care Professionals - Workshop Summary
identifying and balancing potential or actual risk with benefit as information develops over time.
The occurrence of ADEs and the role of consumers and health-care professionals in reporting these events prompted the Forum on Drug Discovery, Development, and Translation to convene a workshop to explore issues associated with reporting of ADEs and to identify actions to improve the drug safety system. The workshop addressed the following questions:
How can ADEs be effectively identified, particularly when the adverse effects are rare?
How can the direct, causal effects of drugs be distinguished from simple associations?
How can health-care professionals and their patients aid in the identification of drug-related adverse events?
How can knowledge of ADEs be more effectively used in clinical practice?
The workshop took place on November 3 and 4, 2005, in Washington, D.C., and was chaired by Jeffrey Drazen, MD, Editor-in-Chief of the New England Journal of Medicine and Professor of Medicine at Harvard Medical School. The reader is referred to Appendixes A and B for the workshop agenda and speaker biographies. Section 2 reviews current sources of information on adverse drug events, including the FDA’s MedWatch program and the AERS, institutional review boards, and the CMS. Section 3 describes surveillance systems, surveillance technology, and data quality. Section 4 considers the ways that consumers and advocacy groups can be involved in reporting adverse events. Section 5 discusses drug interactions, problems with current databases for capturing and evaluating interactions, and difficulties in communicating information about adverse drug interactions. Section 6 describes new requirements for information contained on drug labels and how labels can be used to communicate information about risks and drug interactions to consumers and practitioners.